Two of the FTSE 100's most defensive heavyweights report on the same morning as Chancellor John Healey's first Autumn Budget, giving investors a test of whether "safe haven" stocks can steady a nervous index.

A busy Wednesday for London

Wednesday 28 October 2026 is crowded. GSK (LSE:GSK) publishes third-quarter results, Unilever (LSE:ULVR) issues a third-quarter trading statement, and Standard Chartered (LSE:STAN) and Intertek (LSE:ITRK) also update the market. Later, John Healey stands up to deliver his first Autumn Budget as Chancellor, and in the evening the US Federal Reserve announces its rate decision.

Neither GSK nor Unilever had released its figures ahead of the session. The focus is therefore on the context both companies report into and the kinds of questions investors typically bring to updates from businesses like these.

That context is not especially calm. On Tuesday the FTSE 100 fell 80.79 points, or 0.8%, to 10,686.54, its biggest one-day drop in about a month. HSBC's disappointing quarter, a slide in Reckitt (LSE:RKT) and a weaker oil price that hit BP (LSE:BP.) and Shell (LSE:SHEL) did most of the damage. The FTSE 250 rose 0.9% on the same day, a reminder that the blue-chip index's moves often reflect a handful of very large companies rather than the UK economy as a whole.

GSK and Unilever are both large constituents, and both are often described as defensive. The label refers to the nature of demand: people continue to need medicines and everyday household and personal care products whether the economy is growing or slowing. That tends to make earnings less cyclical than those of banks, miners or oil producers.

Both companies are also global businesses with substantial sales outside the UK. That gives them a different relationship with sterling from domestically focused stocks. When the pound weakens, overseas earnings translate into more pounds, which can flatter reported figures. Sterling slipped to $1.3307 from $1.3353 on Tuesday. A sharp currency reaction to the Budget, which some market commentators suggested could matter more than individual tax measures, would therefore affect these companies differently from, say, a UK housebuilder.

On days when the domestic picture is uncertain, investors sometimes rotate towards international earners for that reason. Whether that happens on Wednesday will depend on both the Budget and the companies' own news.

Unilever: what Reckitt's update adds

The most direct read-across for Unilever came on Tuesday from Reckitt, another FTSE 100 consumer goods group. Reckitt cut its full-year Core Reckitt like-for-like revenue growth guidance to 3.5%–4.5% from 4%–5% after third-quarter growth of 3.3% missed the 3.6% the market had expected. Its shares closed down 4.9% at 5,218p.

Several details are relevant to how investors may approach Unilever's statement, even though the two businesses are different:

  • Volume versus price. Reckitt's Core volumes rose just 0.1%, with price and mix contributing 3.2%. Consumer goods investors pay close attention to whether growth comes from selling more units or from charging more, because volume growth is generally seen as more durable.
  • Regional divergence. Reckitt's Emerging Markets revenue grew 8.0% on a like-for-like basis, while Europe rose 0.8% and North America fell 1.3%. Geographic splits are likely to be scrutinised in Unilever's update too.
  • Competition. Reckitt cited tougher competition for its Finish dishwashing brand, alongside temporary manufacturing constraints for Lysol and a slower China vitamins category.

Domestic retail pricing provides another backdrop. Industry data showed shop price inflation rose to 2.1% in October from 1.4%, a two-and-a-half-year high, adding to calls for the Chancellor to act. For branded goods makers, retail price trends can influence both consumer behaviour and negotiations with supermarkets.

GSK, and the Budget overlay

GSK's results arrive two days before AstraZeneca's on Friday 30 October, giving the market two large pharmaceutical updates in one week. Pharmaceutical results tend to be judged on a familiar set of themes: sales growth across key product areas, progress in the development pipeline, margins, and whether full-year guidance is maintained, raised or trimmed.

The wider week offers a reminder of how much the guidance element can matter. HSBC (LSE:HSBA) raised its pre-tax profit by 32% yet fell 5.4% after missing forecasts and reaffirming rather than raising its targets. Reckitt kept its margin guidance but cut its revenue range and was marked down. Computacenter (LSE:CCC), by contrast, rose 13% on Monday after raising its profit outlook above market expectations. The pattern across the week is that the direction of guidance has often driven the share price reaction more than the quarter itself.

Neither GSK nor Unilever is primarily a UK domestic business, but the Budget can still matter. Corporate tax and cost changes affect UK operations, and the gilt market sets the backdrop for share valuations. On Tuesday the 10-year gilt yield stood at about 5.34%. Some market economists suggested the Budget could prove more of a clearing event, while others warned that rising corporate costs could weaken investment and growth.

Defensive shares are often valued partly on the reliability of their dividends, which makes them sensitive to bond yields: when gilts offer more, income-focused investors have an alternative. A large move in yields after the Budget could therefore influence how GSK and Unilever trade, independently of their own results.

Key dates to watch

  • Wednesday 28 October 2026 – GSK Q3 results; Unilever Q3 trading statement
  • Wednesday 28 October 2026 – UK Autumn Budget; US Federal Reserve rate decision
  • Thursday 29 October 2026 – Haleon (LSE:HLN) Q3 trading statement
  • Friday 30 October 2026 – AstraZeneca (LSE:AZN) Q3 results
  • Thursday 5 November 2026 – Bank of England MPC decision

The bottom line

GSK and Unilever bring weight and, in principle, stability to the FTSE 100 on a day dominated by the Budget. Their results had not been published when this was written, so the outcome is open. What is clear is the lens investors are likely to use: for Unilever, the balance of volume and price, regional trends and competitive pressure, sharpened by Reckitt's guidance cut; for GSK, product growth, pipeline and guidance, with AstraZeneca following on Friday. Against a backdrop of gilt yields above 5% and a possible currency reaction, how these two defensives trade could shape whether the index finds its footing after Tuesday's fall.